Authors
Latest:
Dr Lenz on Frontline Nivolumab Plus Ipilimumab in MSI-H/dMMR mCRCHeinz-Josef Lenz, MD, FACP, discusses updated data for nivolumab plus ipilimumab in MSI-H/dMMR mCRC.
Latest:
Dr Lenz on the Prognostic Value of HER2 Expression in mCRCHeinz-Josef Lenz, MD, FACP, discusses the prognostic value of HER2 expression in patients with KRAS wild-type metastatic colorectal cancer.
Latest:
Dr Lenz on the Association Between HER2 Expression and Treatment Outcomes in mCRCHeinz-Josef Lenz, MD, FACP, discusses the association between HER2 expression and treatment outcomes in metastatic colorectal cancer.
Latest:
Preparing Nurses for Advanced Practice in Oncology and Palliative CareBarbara Daly, PhD, RN, FAAN, and Helen Foley, MSN, AOCNS®, offer highlights of their institution's oncology and palliative care program, which successfully prepares graduates to assume advanced practice roles in these important areas.
Latest:
Patient Selection and Sequencing of NSCLC ADCsThe panel examines which patient populations might benefit most from treatment with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd). Additionally, they explore potential sequencing strategies for these antibody-drug conjugates in second-line and later treatment settings.
Latest:
Dr. Schaider Discusses Drug Resistance for MelanomaHelmut Schaider, MD, associate professor, Dermatology Research Centre, the University of Queensland, discusses adaptive drug resistance for patients with melanoma.
Latest:
Dr. Soares on the Standard of Care in Metastatic Pancreatic CancerHeloisa P. Soares, MD, PhD, discusses the standard of care in metastatic pancreatic cancer.
Latest:
Dr. Arkenau on the Potential of Immunotherapy in Gastric CancerHendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Cannon Research Institute UK, discusses the potential of immunotherapy in gastric cancer.
Latest:
Dr Kuerer on Advancements in Neoadjuvant Systemic Therapies in Breast CancerHenry Kuerer, MD, PhD, FACS, CMQ, on significant advancements in neoadjuvant systemic therapies in breast cancer treatment
Latest:
Controversies and Clinical Trials for DCIS: Margins and Active SurveillanceThe management of ductal carcinoma in situ is one of the most controversial areas in breast cancer management.
Latest:
Burnout in Doctors and Mitigation StrategiesWhat may have worked before to mitigate burnout may no longer work now because we change, and so do our work environments.
Latest:
Dr. Eradat on Rituximab Biosimilar in CD20+ B-Cell Non-Hodgkin Lymphoma and CLLHerbert A. Eradat, MD, discusses the implications of the FDA approval of rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) in patients with CD20-positive B-cell Non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Latest:
Dr. Vargas on the Utility of Sentinel Node Biopsy in Breast CancerHernan Vargas, MD, FACS, a breast surgeon at Virginia Cancer Specialists, discusses the utility of sentinel lymph node biopsy in breast cancer.
Latest:
Dr. Tilly Discusses Study of POLA-R-CHP in DLBCLHerve Tilly, MD, PhD, Centre Henri Becquerel, discusses a study of polatuzumab vedotin combined with rituximab (Rituxan), cyclophosphamide, doxorubicin and prednisone (PLOA-R-CHP) in patients with previously untreated diffuse large B-cell lymphoma.
Latest:
Dr. Carraway on Aza-Nucleoside Combinations in MDSHetty Carraway, MD, Hematology and Oncology, Cleveland Clinic, discusses combination epigenetic therapies including aza-nucleosides and histone deacetylase inhibitors, as well as immunomodulatory therapies, such as lenalidomide for the treatment of myelodysplastic syndromes (MDS).
Latest:
Dr Carraway on Currently Available Treatment Options for AMLHetty E. Carraway, MD, MBA, discusses current treatment strategies available for patients with acute myeloid leukemia.
Latest:
Dr. Okada Discusses Immunotherapy Response Assessment in Neuro-OncologyHideho Okada MD, PhD, discusses the need for a new immunotherapy response assessment in euro-oncology. Okada presented on this topic at the 2015 Annual Meeting of the Society for Neuro-Oncology.
Latest:
Dr. Beltran on the Significance of Genomic Sequencing in Prostate CancerHimisha Beltran, MD, discusses the significance of genomic sequencing in prostate cancer.
Latest:
Dr. Iwata on Final OS Results From the Phase 3 IMpassion130 Trial in TNBCHiroji Iwata, MD, PhD, vice director and chief of Breast Oncology at Aichi Cancer Center Hospital, discusses final overall survival results from the phase 3 IMpassion130 trial in triple-negative breast cancer.
Latest:
Dr. Mamdani on Evaluating the Immunogenicity of STK11/TP53 Co-Mutations in NSCLCHirva Mamdani, MD, discusses the rationale to evaluate the immunogenicity of STK11 and TP53 co-mutations in non–small cell lung cancer.
Latest:
Dr. Mehanna on the Design of the De-ESCALaTE Trial in HPV+ Head and Neck CancerHisham Mehanna, PhD, BMedSc, MBChB, FRCS, chair, Head and Neck Surgery, director, Institute of Head and Neck Studies and Education at the Institute of Cancer and Genomic Sciences, University of Birmingham, discusses the design of the De-ESCALaTE trial in patients with HPV-positive head and neck cancer.
Latest:
Dr. Gieschen on Toxicities Associated With Radiation Therapy in Prostate CancerHolger L. Gieschen, MD, assistant professor, University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the toxicities associated with radiation therapy in prostate cancer.
Latest:
Challenges With a Precision Medicine-Based Approach in OncologyHolli Dilks, PhD, director, Personalized Medicine Operations, Sarah Cannon Research Institute, discusses the challenges associated with having a precision medicine-based approach in the field of oncology.
